MAKO Surgical Corp. and Stanmore Implants Worldwide Ltd. Announce MAKO's Purchase of Stanmore Sculptor Robotic Guidance Arm

MAKO Surgical Corp. and Stanmore Implants Worldwide Ltd. Announce MAKO's
Purchase of Stanmore Sculptor Robotic Guidance Arm

FORT LAUDERDALE, Fla., April 16, 2013 (GLOBE NEWSWIRE) -- MAKO Surgical Corp.
(Nasdaq:MAKO) and Stanmore Implants Worldwide Ltd. today announced that MAKO
has agreed to settle all patent infringement actions and acquire certain
assets of Stanmore related to its Sculptor Robotic Guidance Arm (RGA)
business.

On March 19, 2013, MAKO filed complaints against Stanmore with the U.S.
International Trade Commission and the U.S. District Courts of the Northern
District of California and the District of Massachusetts collectively alleging
infringement of MAKO intellectual property by the Sculptor RGA.

Under the confidential settlement and asset purchase agreements between the
parties, in exchange for a cash payment to Stanmore, MAKO will withdraw all
legal actions and receive Stanmore's robotic business assets and intellectual
property, as well as Stanmore's agreement to withdraw from robotics.

"Stanmore is pleased to have reached closure in this matter," said Michael R.
Mainelli, Jr., President and Chief Executive Officer of Stanmore.

"This agreement both affirms and improves MAKO's intellectual property
position in robotically assisted orthopedic surgery," said Maurice R. Ferré,
M.D., President and Chief Executive Officer of MAKO."Moreover, we are
enthused about the possibility of partnering with Stanmore on potential future
projects."

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its RIO®
Robotic-Arm Interactive Orthopedic system, with specific applications for
partial knee resurfacing and total hip replacement, and proprietary RESTORIS®
Family of Implants for orthopedic procedures called MAKOplasty®. The RIO is a
surgeon-interactive tactile surgical platform that incorporates a robotic arm
and patient-specific visualization technology, which enables accurate,
consistently reproducible bone resection for accurate insertion and alignment
of RESTORIS knee and hip implants. The MAKOplasty solution incorporates
technologies enabled by an intellectual property portfolio including more than
300 U.S. and foreign, owned and licensed, patents and patent applications.
Additional information can be found at www.makosurgical.com.

About Stanmore Implants

Stanmore Implants is a commercial-stage orthopaedic implant company focused on
providing differentiated technologies designed to provide solutions for
several important, yet underserved market segments. Stanmore's implant design
service alongside its portfolio of orthopaedic implants draws on over 60
years' experience in providing some of the world's most successful implants in
Extreme Orthopedics.Stanmore is backed by leading investors including
Abingworth, Imperial Innovations and Ivy Capital and intends to seek
like-minded co-investors in 2013 to further support the commercialisation and
growth opportunities offered by its unique technologies and market
positioning.

"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo, whether
standing alone or in connection with the words "MAKO Surgical Corp." are
trademarks of MAKO Surgical Corp.

CONTACT: MAKO Surgical Corp.
         954-628-1706
         investorrelations@makosurgical.com
 
Press spacebar to pause and continue. Press esc to stop.